drugset / Trial / NCT04853147

Triple Therapy for Postoperative Nausea and Vomiting in Laparoscopic Gastrointestinal Surgery

NCT04853147

Phase 3 Completed 1154 enrolled Sixth Affiliated Hospital, Sun Yat-sen University
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Postoperative nausea and vomiting (PONV) are common in patients, especially in patients at high risk. PONV may result in prolonged hospital stay and threaten patients' life. Because the etiology of PONV is very complex, there is an increasing focus on combining antiemetics from different classes for PONV prophylaxis. Fosaprepitant is a neurokinin-1 (NK-1) receptor antagonist to prevent PONV. Palonosetron is a 5-HT3 receptor antagonist with high efficacy and sustained action for PONV prophylaxis. Dexamethasone belongs to corticosteroid and also has the ability to reduce the incident of PONV. This study aims to use the combination of these three drugs in high-risk patients to test whether triple therapy is better than combination of palonosetron and dexamethasone to prevent PONV.

Timeline

Start
2021-04-27
Primary completion
2022-04-13
Completion
2022-10-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Fosaprepitant Other / unclassified 150 mg Intravenous
Background Dexamethasone Small molecule 5 mg Intravenous
Background Palonosetron Other / unclassified 0.075 mg Intravenous

Indications

No indication recorded.